Effect of Dexmedetomidine on Acute Kidney Injury After Ascending Aortic Surgeries

Phase 1 Active not recruiting 78 enrolled Ain Shams University

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Acute kidney injury (AKI) is a frequent and serious complication after ascending aortic surgeries requiring cardiopulmonary bypass (CPB). Dexmedetomidine, a selective α-2 adrenoreceptor agonist, may reduce AKI because of its sympatholytic and anti-inflammatory effects against ischaemia reperfusion injury. We investigate the effect of dexmedetomidine administration on AKI after ascending aortic surgeries requiring CPB in a placebo-controlled randomised controlled trial.

Timeline

Start: 2025-11-01
Primary completion: 2026-11-02
Completion: 2026-11-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Dexmedetomidine	Other / unclassified	0.4 ug/kg	—

Indications

No indication recorded.